Antibody

1,032개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,032 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleFudan UniversityPhase 2

Cromolyn, TQB2102, and Panpulimab (Cromolyn, TQB2102, and Panpulimab)

Triple -Negative Breast Cancer · Triple -Negative Breast Cancer

#Triple-NegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Cryoablation Combined with Tirelizumab and Bevacizumab (Cryoablation Combined with Tirelizumab and Bevacizumab)

Metastatic Breast Cancer in the Liver · Metastatic Breast Cancer in the Liver

#MetastaticBreastCancerintheLiver#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleJanssenPhase 3

daratumumab (Darzalex, Cyclo Thal Dex Daratumumab)

Multiple Myeloma Stage I · Multiple Myeloma Stage I

#MultipleMyelomaStageI#Antibody#Phase3#monoclonal-antibody#Janssen
Trials 1Status Active
AntibodyLimited DatastaleMedical College of WisconsinPhase 3

Cyclophosphamide and Rituximab (Cyclophosphamide and Rituximab)

Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 1 Follicular Lymphoma

#RecurrentGrade1FollicularLymphom#Antibody#Phase3#monoclonal-antibody#RecurrentGrade2FollicularLymphom+1
Trials 1Status Discontinued
AntibodyLimited DatastaleHeidelberg UniversityPhase 2

Cyclophosphamide, Pentostatin, Rituximab (Cyclophosphamide, Pentostatin, Rituximab)

Immunocytoma/Morbus Waldenström; B-Cell Non-Hodgkin's Lymphoma · Immunocytoma/Morbus Waldenström

#ImmunocytomaMorbusWaldenstrm#Antibody#Phase2#monoclonal-antibody#Immunocytoma+3
Trials 1Status Active
AntibodyLimited DatastaleScripps HealthPreclinical

Cyclophosphamide/Rituximab (Cyclophosphamide/Rituximab)

Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Preclinical#monoclonal-antibody#MultipleSclerosis+2
Trials 1Status Discontinued
AntibodyLimited DatastaleDong-A ST Co., Ltd.Phase 2

pembrolizumab (Keytruda, DA-4505 + Pembrolizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase2#monoclonal-antibody#Dong-A
Trials 1Status Recruiting
AntibodyLimited DatastaleFudan UniversityPreclinical

DEBIRI Combined With Chemotherapy and Bevacizumab (DEBIRI Combined With Chemotherapy and Bevacizumab)

Colorectal Neoplasms · Colorectal Neoplasms

#ColorectalNeoplasms#Antibody#Preclinical#monoclonal-antibody#Fudan
Trials 1Status Active
AntibodyLimited DatastaleKahr Bio Australia Pty LtdPhase 2

atezolizumab (Tecentriq, DSP107 + Atezolizumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#Kahr
Trials 1Status Recruiting
AntibodyLimited DatastaleSanofiPhase 1

dupilumab (DUPIXENT®, DUPIXENT® (dupilumab))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#monoclonal-antibody#Sanofi
Trials 1Status Recruiting
AntibodyLimited DatastaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Dizal
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Eye Institute (NEI)Phase 1

Zenapax (Daclizumab, Daclizumab (Zenapax))

Uveitis · Uveitis

#Uveitis#Antibody#Phase1#monoclonal-antibody#National
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

Dalpiciclib+cetuximab (Dalpiciclib+cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Dalpicilib combined with cetuximab (Dalpicilib combined with cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 1

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Darzalex Faspro (Daratumumab and hyaluronidase-fihj))

Hematologic Malignancy; Bone Marrow Transplant Rejection · Hematologic Malignancy

#HematologicMalignancy#Antibody#Phase1#monoclonal-antibody#BoneMarrowTransplantRejection+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 1Status Recruiting
AntibodyLimited DatastaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#monoclonal-antibody#OncoMed
Trials 1Status Active
AntibodyLimited DatastaleCedars-Sinai Medical CenterPhase 1

Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab (Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#Antibody#Phase1#monoclonal-antibody#GlioblastomaMultiforme+1
Trials 1Status Active
AntibodyLimited DatastaleAmgenPhase 3

AMG 162 (Denosumab, Denosumab (AMG 162))

Postmenopausal Osteoporosis · Postmenopausal Osteoporosis

#PostmenopausalOsteoporosis#Antibody#Phase3#monoclonal-antibody#Amgen
Trials 1Status Active

24 / 52 pages

← PreviousNext →